Overview

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

Status:
Completed

Trial end date:
2015-12-15

Target enrollment:

Participant gender:

Summary

This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen
Celgene Corporation

Treatments:

Apremilast
Thalidomide